-+ 0.00%
-+ 0.00%
-+ 0.00%

On the evening of July 15, Hisco announced that the company recently received a Study May Proceed Letter from the US Food and Drug Administration. According to relevant FDA regulations, after review, the clinical trial application for HSK47388 tablets submitted by the company in May 2025 met the relevant requirements for drug registration and agreed to conduct clinical trials with this product. HSK47388 tablets are intended for the treatment of autoimmune diseases.

Zhitongcaijing·07/15/2025 09:25:07
Listen to the news
On the evening of July 15, Hisco announced that the company recently received a Study May Proceed Letter from the US Food and Drug Administration. According to relevant FDA regulations, after review, the clinical trial application for HSK47388 tablets submitted by the company in May 2025 met the relevant requirements for drug registration and agreed to conduct clinical trials with this product. HSK47388 tablets are intended for the treatment of autoimmune diseases.